Reata Pharmaceuticals Inc (NASDAQ:RETA)

25.17
Delayed Data
As of Sep 30
 +0.14 / +0.56%
Today’s Change
18.47
Today|||52-Week Range
114.80
-4.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$910.6M

Company Description

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Contact Information

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano Texas 75024
P:(972) 865-2219
Investor Relations:
(469) 442-4883

Employees

Shareholders

Other institutional47.82%
Mutual fund holders29.59%
Individual stakeholders23.78%

Top Executives

J. Warren HuffChairman & Chief Executive Officer
Manmeet Singh SoniPresident, Chief Operating & Financial Officer
W. Christian WigleyChief Scientific Officer & Senior Vice President
Edmund DohertyVice President-Medical Affairs
Samina KhanChief Medical Officer & Senior Vice President